Treatment-related cardiovascular late effects and exercise training countermeasures in testicular germ cell cancer survivorship

Acta Oncologica

Volumn 54, Issue 5, 2015, Pages 592-599

  Christensen, Jesper F ^a,b,e   Bandak, Mikkel ^b   Campbell, Anna ^c   Jones, Lee W ^d   Højman, Pernille ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Mental Health Center Glostrup   (Denmark)

^c UNIVERSITY OF SURREY   (United Kingdom)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e Centre for Physical Activity Research (CFAS)   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; BLEOMYCIN; CISPLATIN; ETOPOSIDE; GLUCOCORTICOID; PREDNISOLONE; ANTINEOPLASTIC AGENT;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER SURVIVOR; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; EXERCISE; GERM CELL TUMOR; HUMAN; MALE; ORCHIECTOMY; PRIORITY JOURNAL; REVIEW; TESTIS CANCER; ADAPTATION; ADVERSE EFFECTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR FUNCTION; MUSCLE CONTRACTION; NEOPLASMS, GERM CELL AND EMBRYONAL; PHYSIOLOGY; PROCEDURES; RADIOTHERAPY; RESISTANCE TRAINING; SURVIVOR; TESTICULAR NEOPLASMS; YOUNG ADULT;

ADAPTATION, PHYSIOLOGICAL; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; EXERCISE; GLUCOCORTICOIDS; HUMANS; MALE; MUSCLE CONTRACTION; NEOPLASMS, GERM CELL AND EMBRYONAL; ORCHIECTOMY; RADIOTHERAPY; RESISTANCE TRAINING; SURVIVORS; TESTICULAR NEOPLASMS; YOUNG ADULT;

EID: 84928797199     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2014.995776     Document Type: Review

References (39)

1. Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977; 87: 293-8.
2. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, et al. Recent cancer survival in Europe: A 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007; 8: 784-96.
3. Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: A 20-year follow-up study. J Clin Oncol 2010; 28: 4649-57.
4. Fossa SD, Gilbert E, Dores GM, Chen J, McGlynn KA, Schonfeld S, et al. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 2007; 99: 533-44.
5. Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, et al. Maintaining success, reducing treatment burden, focusing on survivorship: Highlights from the third European consensus conference on diagnosis and treatment of germcell cancer. Ann Oncol 2013; 24: 878-88.
6. Thompson PD, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: A statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003; 107: 3109-16.
7. Gielen S, Schuler G, Adams V. Cardiovascular effects of exercise training: Molecular mechanisms. Circulation 2010; 122: 1221-38.
8. Buffart LM, Galvao DA, Brug J, Chinapaw MJ, Newton RU. Evidence-based physical activity guidelines for cancer survivors: Current guidelines, knowledge gaps and future research directions. Cancer Treat Rev 2014; 40: 327-40.
9. Jones LW, Liang Y, Pituskin EN, Battaglini CL, Scott JM, Hornsby WE, et al. Effect of exercise training on peak oxygen consumption in patients with cancer: A meta-analysis. Oncologist 2011; 16: 112-20.
10. Irwin ML, Alvarez-Reeves M, Cadmus L, Mierzejewski E, Mayne ST, Yu H, et al. Exercise improves body fat, lean mass, and bone mass in breast cancer survivors. Obesity (Silver Spring) 2009; 17: 1534-41.
11. Pekmezi DW, Demark-Wahnefried W. Updated evidence in support of diet and exercise interventions in cancer survivors. Acta Oncol 2011; 50: 167-78.
12. Huyghe E, Plante P, Thonneau PF. Testicular cancer variations in time and space in Europe. Eur Urol 2007; 51: 621-8.
13. Haugnes HS, Aass N, Fossa SD, Dahl O, Klepp O, Wist EA, et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007; 18: 241-8.
14. Nuver J, Smit AJ, Wolffenbuttel BH, Sluiter WJ, Hoekstra HJ, Sleijfer DT, et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005; 23: 3718-25.
15. Willemse PM, Burggraaf J, Hamdy NA, Weijl NI, Vossen CY, van Wulften L, et al. Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors. Br J Cancer 2013; 109: 60-7.
16. Bandak M, Aksglaede L, Juul A, Rorth M, Daugaard G. The pituitary-Leydig cell axis before and after orchiectomy in patients with stage Itesticular cancer. Eur J Cancer 2011; 47: 2585-91.
17. Traish AM, Saad F, Feeley RJ, Guay A. The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl 2009; 30: 477-94.
18. Bobjer J, Katrinaki M, Tsatsanis C, Lundberg GY, Giwercman A. Negative association between testosterone concentration and inflammatory markers in young men: A nested cross-sectional study. PLoS One 2013; 8: e61466.
19. Christensen JF, Tolver A, Andersen JL, Rorth M, Daugaard G, Hojman P. Resistance training does not protect against increases in plasma cytokine levels among germ cell cancer patients during and after chemotherapy. J Clin Endocrinol Metab 2014; 99: 2967-76.
20. Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003; 21: 1513-23.
21. Zagars GK, Ballo MT, Lee AK, Strom SS. Mortality after cure of testicular seminoma. J Clin Oncol 2004; 22: 640-7.
22. Lauritsen J. Risk of cardiovascular disease, diabetes and death in germ-cell cancer survivors in a large cohort. Eur J Cancer 2013; 49(Suppl 2).
23. Wethal T, Kjekshus J, Roislien J, Ueland T, Andreassen AK, Wergeland R, et al. Treatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancer. J Cancer Surviv 2007; 1: 8-16.
24. van den Belt-Dusebout AW, Nuver J, de Wit R, Gietema JA, ten Bokkel Huinink WW, Rodrigus PT, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006; 24: 467-75.
25. Nuver J, Smit AJ, van der Meer J, van den Berg MP, van der Graaf WT, Meinardi MT, et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 2005; 23: 9130-7.
26. Meinardi MT, Gietema JA, van der Graaf WT, van Veldhuisen DJ, Runne MA, Sluiter WJ, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18: 1725-32.
27. Christensen JF, Jones LW, Tolver A, Jorgensen LW, Andersen JL, Adamsen L, et al. Safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy: A randomized controlled trial. Br J Cancer 2014; 111: 8-16.
28. Hojman P, Fjelbye J, Zerahn B, Christensen JF, Dethlefsen C, Lonkvist CK, et al. voluntary exercise prevents cisplatininduced muscle wasting during chemotherapy in mice. PLoS One 2014; 9: e109030.
29. van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: Towards expansion of therapeutic options? Eur J Clin Invest 2009; 39: 81-93.
30. Short KR, Bigelow ML, Nair KS. Short-term prednisone use antagonizes insulin's anabolic effect on muscle protein and glucose metabolism in young healthy people. Am J Physiol Endocrinol Metab 2009; 297: E1260-8.
31. Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007; 50: 1435-41.
32. Koelwyn GJ, Khouri M, Mackey JR, Douglas PS, Jones LW. Running on empty: Cardiovascular reserve capacity and late effects of therapy in cancer survivorship. J Clin Oncol 2012; 30: 4458-61.
33. Rose AJ, Richter EA. Skeletal muscle glucose uptake during exercise: How is it regulated? Physiology (Bethesda) 2005; 20: 260-70.
34. Egan B, Zierath JR. Exercise metabolism and the molecular regulation of skeletal muscle adaptation. Cell Metab 2013; 17: 162-84.
35. Pedersen BK. Exercise-induced myokines and their role in chronic diseases. Brain Behav Immun 2011; 25: 811-6.
36. Pedersen BK, Saltin B. Evidence for prescribing exercise as therapy in chronic disease. Scand J Med Sci Sports 2006; 16(Suppl 1): 3-63.
37. Adamsen L, Quist M, Andersen C, Moller T, Herrstedt J, Kronborg D, et al. Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: Randomised controlled trial. Br Med J 2009; 339: b3410.
38. Thorsen L, Skovlund E, Stromme SB, Hornslien K, Dahl AA, Fossa SD. Effectiveness of physical activity on cardiorespiratory fitness and health-related quality of life in young and middle-aged cancer patients shortly after chemotherapy. J Clin Oncol 2005; 23: 2378-88.
39. Einhorn LH. Treatment of testicular cancer: A new and improved model. J Clin Oncol 1990; 8: 1777-81.